Differential actions of acute and chronic citalopram on the rodent hypothalamic-pituitary-adrenal axis response to acute restraint stress.

Hesketh S, Jessop DS, Hogg S, Harbuz MS

The Journal of endocrinology1 Jun 2005Cited by 38 (Europe PMC)

PMID15930163DOI10.1677/joe.1.06074PepBankPUB-15930163

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Natural levels measured5

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01AnimalEndogenous levelAnimal study (in vivo)Mechanism
In rats, citalopram increased oxytocin mRNA in the magnocellular paraventricular nucleus.
In plain wordsIn rats, citalopram raised the body's own oxytocin gene activity in one brain area.
Peptide
Oxytocin
Outcome
IncreaseOxytocin mRNA in magnocellular PVN after citalopram
Study
ratn: not reported in source
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
Oxytocin (OT) mRNA was also increased in the magnocellular PVN (mPVN) by the solo treatments of citalopram and restraint, and was not further enhanced by the dual treatment of restraint and citalopram.
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of this work was to investigate the rodent HPA axis response to restraint stress, following acute and chronic treatment with the SSRI citalopram.
This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-1593016301
02AnimalEndogenous levelAnimal study (in vivo)Mechanism
In rats, acute restraint stress increased oxytocin mRNA in the magnocellular paraventricular nucleus.
In plain wordsIn rats, restraint stress raised the body's own oxytocin gene activity in one brain area.
Peptide
Oxytocin
Outcome
IncreaseOxytocin mRNA in magnocellular PVN after restraint
Study
ratn: not reported in source
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
Oxytocin (OT) mRNA was also increased in the magnocellular PVN (mPVN) by the solo treatments of citalopram and restraint, and was not further enhanced by the dual treatment of restraint and citalopram.
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of this work was to investigate the rodent HPA axis response to restraint stress, following acute and chronic treatment with the SSRI citalopram.
This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-1593016302
03AnimalEndogenous levelAnimal study (in vivo)Mechanism
In rats, citalopram together with restraint did not raise oxytocin mRNA in the magnocellular paraventricular nucleus further than either treatment alone.
In plain wordsIn rats, citalopram plus restraint did not raise the body's own oxytocin gene activity more than either one alone.
Peptide
Oxytocin
Outcome
No significant changeOxytocin mRNA in magnocellular PVN after citalopram plus restraint
Study
ratn: not reported in source
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
Oxytocin (OT) mRNA was also increased in the magnocellular PVN (mPVN) by the solo treatments of citalopram and restraint, and was not further enhanced by the dual treatment of restraint and citalopram.
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of this work was to investigate the rodent HPA axis response to restraint stress, following acute and chronic treatment with the SSRI citalopram.
This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-1593016303
04AnimalEndogenous levelAnimal study (in vivo)Mechanism
In rats, chronic citalopram infusion did not raise oxytocin mRNA in the magnocellular paraventricular nucleus.
In plain wordsIn rats, long-term citalopram did not raise the body's own oxytocin gene activity in one brain area.
Peptide
Oxytocin
Outcome
No significant changeOxytocin mRNA in magnocellular PVN after chronic citalopram
Study
ratn: not reported in source
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
OT mRNA was not enhanced in the mPVN following chronic infusion of citalopram but was increased by acute restraint stress.
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of this work was to investigate the rodent HPA axis response to restraint stress, following acute and chronic treatment with the SSRI citalopram.
This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-1593016304
05AnimalEndogenous levelAnimal study (in vivo)Mechanism
In rats given chronic citalopram, acute restraint stress increased oxytocin mRNA in the magnocellular paraventricular nucleus.
In plain wordsIn rats, restraint stress raised the body's own oxytocin gene activity in one brain area.
Peptide
Oxytocin
Outcome
IncreaseOxytocin mRNA in magnocellular PVN after acute restraint (chronic citalopram study)
Study
ratn: not reported in source
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
OT mRNA was not enhanced in the mPVN following chronic infusion of citalopram but was increased by acute restraint stress.
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of this work was to investigate the rodent HPA axis response to restraint stress, following acute and chronic treatment with the SSRI citalopram.
This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-1593016305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 20:03 UTC
Study results updated
Version 1
9 Oct 2026, 02:53 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.